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Brody’s instrumental activities of daily living.
Apart from age, both cohorts were well matched for baseline char-
acteristics. The median age of patients undergoing RIC was signifi-
cantly higher to those undergoing MY conditioning (59 vs. 42 yrs,
p\0.0001). The compliance for completion of QOL assessments
was: baseline, 98%; Day30, 91%; day100, 85%; day180, 84%; and
day365, 85%. The main reason for non-compliance was illness due
to toxicity or disease relapse.
QOL data were analyzed for both cohorts without imputation.
QOL scores did not differ for the two study groups at baseline.
There was a decline in QOL scores in post transplant period
with lowest scores at day30 followed by subsequent slow improve-
ment to baseline by day365. The RIC cohort had better QLQ-
C30 scores in the domains of physical functioning (p5 0.005)
and role functioning (p5 0.02) at day30. No other significant dif-
ferences were noted between the two groups at other time points.
Recovery post transplant was similar in the two cohorts. In a mul-
tivariate analysis, clinically meaningful differences in favor of RIC
cohort were observed in the role functioning domain of QLQ-
C30. In addition, patients with HCT-comorbidity scores$ 3
had significantly worse scores for emotional functioning and
global health domain of QLQC-30, FACT-BMT, FACT-An
and HADS.
Imputing QOL data using worst scores for patients who did not
complete QOL questionnaire due to illness did not significantly in-
fluence the above results.
We conclude that both MY and RIC regimens resulted in similar
QOL at 1-year post transplant.191
IMPLEMENTATION OF A HEMATOLOGICAL MALIGNANCY-BASED SURVI-
VORSHIP CLINIC
Asher, A., Steinberg, A. Cedars-Sinai Medical Center, Los Angeles, CA
Background: There are approximately 12 million cancer survivors
in the U.S. Cancer survivors are at increased risk for health compli-
cations such as heart disease, secondary malignancies, and psycho-
logical distress. Reflecting the needs of cancer survivors as part of
our health care system, the Institute of Medicine issued a seminal re-
port, From Cancer Patient to Cancer Survivor: Lost in Transition,
recognizing cancer survivorship as a ‘‘distinct phase of cancer
care.’’ A dedicated survivorship clinic with creation of personal
care plans and treatment summaries can serve the needs of this grow-
ing cohort of patients.
Objective: To determine the viability of a transplant/hematological
malignancy-based survivorship clinic with treatment summary and
care plan for survivors.
Methods: A literature search was initiated examining recommenda-
tions and guidelines regarding follow-up of cancer patients. We in-
corporated and consolidated guidelines from ASCO, NMDP,
NCCN, and COG, pertinent articles from the PubMed database,
and the growing literature for cancer survivorship. Awareness of
the program was to be initiated with letters to affiliated physicians,
lecture series, patient-oriented educational handouts, and articles
in the hospital literature.
Data Synthesis: A treatment care plan was devised for all survi-
vorship clinic patients. This care plan summarized patients’ prior
care with recommendations for follow-up such as cardiac and can-
cer screening, osteoporosis, thyroid disease, and vaccination
schedules–all based on our consolidative review of available evi-
dence-based or expert guidelines. A referral base was developed
with specialists focused on lymphedema, psychiatric issues (needs
determined by screening tools), social work, art therapy, exercise,
and nutrition.
Results: Patients from affiliated hematologists/oncologists were
seen in the survivorship clinic. Unique care plans were devised for
them based on their history of having had a hematologic malignancy
or a stem cell transplant. A satisfaction survey was to be imple-
mented. Preliminary satisfaction from both physicians and the pa-
tients themselves was positive.Conclusion: A transplant/hematologic malignancy-based survivor-
ship clinic is feasible and fills an important need in a large, urban,
hospital-based cancer center. Further investigation will focus on de-
veloping a computer-based treatment summary and care plan, in-
creasing patient referrals, and developing a lecture series devoted
to survivorship.192
OUTCOME OF SOLID ORGAN TRANSPLANT FOLLOWING BLOOD AND
MARROW TRANSPLANT (BMT) IN PEDIATRIC PATIENTS
Guzikowski, V., Bunin, N. Children’s Hospital of Philadelphia, PA
Blood and marrow transplant (BMT) may be curative for children
with malignancies as well as life-threatening non-malignant diseases.
However, permanent organ failure may result from conditioning
regimens or other BMT-related toxicities. Solid organ transplant
(SOT) may be indicated for a select group of pediatric patients,
but this poses difficult decisions for families and caregivers. There
is limited information available about the outcome of children who
received SOT following BMT. At the Children’s Hospital of Phila-
delphia, we have identified eight children (4 males) who have re-
ceived a solid organ transplant following a BMT. Patients (pts)
were 6 months to 18 years at the time of BMT. Diseases for which
BMT was indicated included: thalassemia, Wiskott-Adrich syn-
drome, Shwachman-Diamond/bone marrow failure, sickle cell dis-
ease (SCD), erythopoetic porphyria (EP), acute lymphoblastic
leukemia, chronic granulamotous disease, and neuroblastoma. BM
donors were matched sibling in 4, unrelated in 3, and autologous
for one. Time from BMT to SOT was 13 days-7 years (median, 27
months), with two pts\2 months who received liver transplants. In-
dications for liver transplant included VOD (2), chronic GVHD
(1).Lung SOT was performed for 2 pts with bronchiolitis obliterans
(2), and kidney transplants for 3 pts with renal failure. Three of the
organs were from a living related donor (2- liver, 1-kidney), and 5
were cadaveric organs. Four pts were on immunosuppressant agents
at the time of the SOT: 2 pts\2 months from BMT on a cyclospor-
ine infusion, one pt on tacrolimus for treatment of BOOP, and one pt
with EP on both azathioprine and prednisone due to a previous liver
transplant. Seven pts (2-lungs, 2-liver, 3-kidney) are alive with func-
tioning allografts two to 157 months from SOT. One pt with thalas-
semia developed multiple mesenteric artery thromboses following
two attempts at liver transplant and died. Advances in organ procure-
ment, operative technique, immunosuppressant therapy and infec-
tion control may allow SOT for a select group of pts post BMT.
However, scarcity of donor organs available in a timely fashion
continues to be a limiting factor. Children who have undergo
BMT and develop single organ failure should be considered for
a solid organ transplant if there is a high likelihood of cure of the
primary disease.193
FIRST DESCRIPTION OF A SUCCESSFUL PREGNANCY AFTERMYELOABLA-
TIVE STEM CELL TRANSPLANTATION IN A SICKLE CELL PATIENT BY
MEANS OF AN OVARIAN TISSUE AUTOGRAFT
Roux, C.1,5, Amiot, C.1,5, Agnani, G.2, Aubard, Y.3, Deconinck, E.4,5,
Piver, P.3, Rohrlich, P.S.4,5 1CHU Hopital Saint Jacques, Besancon,
France; 2CHU Hopital Saint Jacques, Besancon, France; 3CHU Hopital
Me`re et Enfant, Limoges, France; 4CHUHopital Jean Minjoz, Besancon,
France; 5UMR 645 INSERM/UFC/EFS BFC, Besancon, France
The preservation of fertility is an emerging concern in patients
treated by myeloablative hematopoietic stem cell transplantation
(HSCT). One major drawback of autologous gonadic tissue trans-
plant being the risk of leukemia recurrence, this procedure is first
to be proposed to patients allografted for non malignant diseases.
Cryopreservation of ovarian tissue with subsequent autotransplanta-
tion is an emerging procedure that has led to 6 reported births until
today, none of them being obtained after HSCT. Moreover, 3 of
these 6 pregnancies were obtained through in vitro fertilization pro-
cedures. We report the restoration of ovarian activity followed by
pregnancy and live birth after an orthotopic transplantation of ovar-
ian tissue in a 19 year old female patient transplanted for sickle cell
anemia. The patient having experienced a CNS stroke received an
